Reach, Acceptability, and Effectiveness of Proactive Outreach and Varenicline with Cancer-Focused Counseling for Patients with Cancer: A Pilot Randomized Comparative Effectiveness Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41883352.
- Also identified by DOI 10.1200/oa-25-00169 and PMC identifier 13012660.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
More research is needed on the acceptability and effectiveness of cigarette smoking cessation treatments for patients with cancer. This pilot comparative effectiveness trial contrasted varenicline therapy combined with cancer-focused counseling versus standard smoking cessation treatment to assess the reach, acceptability, and preliminary effectiveness of targeted treatment offered proactively to adult patients with cancer. Electronic health records identified adult patients via quarterly reports (January-September, 2024) with cancer diagnoses who smoked tobacco in the past year (N=574) for tobacco use treatment outreach. Eligible patients were enrolled from March-November, 2024, in an effectiveness trial comparing standard smoking cessation treatment (2w nicotine patch + 3 counseling calls) with enhanced treatment (12w varenicline + 7 cancer-targeted counseling calls). Follow-up outcome calls were conducted 12- and 26-weeks after a target quit date. Participants reporting no smoking at 26 weeks post-quit were asked to provide a saliva or breath sample to confirm abstinence. Among patients eligible at the time of phone outreach (n=406), 52 (12.8%) enrolled in the trial. In both Standard Care (n=26) and Enhanced Care (n=26), at least 23 (88.5%) participants completed some counseling and received study medications. Satisfaction ratings were higher in Enhanced than Standard Care. At 12 weeks post-quit, self-reported 7-day point prevalence abstinence was reported by 6 (23.1%) Standard Care and 9 (34.6%) Enhanced Care participants (OR 1.76, 95%CI 0.52, 5.97). At 26-weeks post-quit, 2 (7.7%) Standard Care and 7 (26.9%) Enhanced Care participants had biochemically confirmed abstinence (OR: 4.4, 95%CI, 0.82-23.8). This pilot study produced evidence supporting the reach, acceptability, and potential effect sizes of enhanced and cancer-focused smoking cessation counseling and medication treatment for adult patients with cancer.